CRISPR Therapeutics announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug Administration’s Cellular, Tissue, and Gene Therapies Advisory Committee is meeting today to review the Biologics License Application for exagamglogene autotemcel) for the treatment of sickle cell disease in people ages 12 and older with recurrent vaso-occlusive crises. The Prescription Drug User Fee Act date for completion of the review of the BLA for exa-cel for SCD is December 8, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
- CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
- Crispr Therapeutics put volume heavy and directionally bearish
- Crispr exa-cel AdCom briefing docs a ‘possible best case,’ says Mizuho
- FDA staff raise concerns about Vertex, Crispr sickle cell therapy safety data